Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2005-06-14
2005-06-14
McKenzie, Thomas C. (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S254010, C514S254050, C514S225200, C514S255030, C544S337000, C544S360000, C544S366000, C544S372000, C544S384000, C544S389000, C544S390000, C544S391000, C544S403000
Reexamination Certificate
active
06906074
ABSTRACT:
A 2-phenylpiperazine derivative represented by the formula (I) or a pharmaceutically acceptable salt, hydrate, or complex thereof:wherein each of X1and X3is oxygen or two hydrogen atoms, X2O, NH, NCH3, or CH2, n is an integer of 0 or 1, R1is hydrogen or lower alkyl and R2is hydrogen, cyano, tetrazolyl, aminotriazolyl , mesyl, t-butoxycarbonyl, or a lower alkyl which may be optionally substituted, R3is hydrogen, halogen, lower alkyl or lower alkoxy, each of R4and R5is hydrogen, lower alkoxy or trifluoromethyl, and a broken line indicates a single or double bond. The derivative may be used as a tachykinin antagonist in the treatment of diseases of the digestive system, nervous system and respiratory system, inflammation, allergy, carcinoid syndrome, chronic pain, headache, Crohn disease, depression and vomiting.
REFERENCES:
patent: 5472978 (1995-12-01), Baker et al.
patent: 5610183 (1997-03-01), Owens et al.
patent: 5629347 (1997-05-01), Swain et al.
patent: 5719156 (1998-02-01), Shue et al.
patent: 5795894 (1998-08-01), Shue et al.
patent: 5798359 (1998-08-01), Shue et al.
patent: 5892039 (1999-04-01), Shue et al.
patent: 5981520 (1999-11-01), Shue et al.
patent: 2271774 (1994-04-01), None
patent: 6509332 (1993-01-01), None
patent: 6509087 (1995-12-01), None
patent: 6509090 (1997-03-01), None
patent: WO 01/70708 (2001-09-01), None
Chawla SP, Grunberg SM, Gralla RJ, Hesketh PJ, Rittenberg C, Elmer ME, Schmidt C, Taylor A, Carides AD, Evans JK, Horgan KJ., Cancer. May 1, 2003;97(9):2290-300.
Ranga K, Krishnan R, J Clin Psychiatry. 2002; 63 Suppl 11:25-9, Medline abstract PMID: 12562140.
West, Anthony R., Solid State Chemistry and its Applications, Wiley, New York, 1988, pp. 358 & 365.
Williams et al.,Acyclic NK-1 Antagonists: 2-Benzhydryl-2-Aminoethyl Ethers, Bioorganic & Medicinal Chemistry Letters, vol. 4, No. 16, pp. 1903-1908, 1994.
Stevenson et al.,4,4-Disubstituted Piperidine High-affinity NK1Antagonists: Structure—Activity Relationships and in Vivo Activity, J. Med. Chem., 41, pp. 4623-4635, 1998.
Vedani et al.,Multiple-Conformation and Protonation-State Representation in 4D-QSAR: The Neurokinin-1 Receptor System, J. Med. Chem., 43, pp. 4416-4427, 2000.
Furukawa Kazuhito
Higashiura Kunihiko
Konishi Yukari
Ogino Takashi
Hollander Law Firm, P.L.C.
McKenzie Thomas C.
Nippon Zoki Pharmaceutical Co. Ltd.
LandOfFree
2-phenylpiperazine derivatives does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 2-phenylpiperazine derivatives, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 2-phenylpiperazine derivatives will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3461565